InDevR licenses Mount Sinai influenza antibodies for VaxArray neuraminidase potency assay

(InDevR, Inc.) InDevR advances its VaxArray technology toward tracking neuraminidase levels in flu vaccines through an exclusive, worldwide antibody license agreement with the Icahn School of Medicine at Mount Sinai.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news